Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide
Open Access
- 28 January 2013
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (9) , 1965-1974
Abstract
Lenalidomide (LEN) treatment in multiple myeloma (MM) results in a superior outcome. However, there is concern for increased myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) associated with LEN. Thus, bone marrow morphology and cytogenetics studies from 40 patients were evaluated for early signs of MDS prior to therapy, during therapy and at follow-up. Newly diagnosed patients with MM treated with LEN and dexamethasone (LD) alone or followed by autologous stem cell transplant (LD/ASCT), or patients with relapsed/refractory MM treated with LEN, bendamustine and dexamethasone (BLD) were included. One patient developed MDS. Baseline prevalence of mild morphologic myelodysplasia was highest in pretreated patients with MM (BLD, 71%), but was also seen in newly diagnosed patients (LD and LD/ASCT, 17%). The prevalence of myelodysplasia did not increase over time. Thus, this study did not reveal rapidly emerging MDS in 39 of 40 patients with MM treated with LEN. The development of MDS in one patient suggests that longer follow-up is needed for all.Keywords
This publication has 54 references indexed in Scilit:
- Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation studyBlood, 2012
- Second malignancies after multiple myeloma: from 1960s to 2010sBlood, 2012
- NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insightsBlood, 2011
- Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Blood, 2011
- The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply)Haematologica, 2011
- FISH and SNP-A karyotyping in myelodysplastic syndromes: Improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q)Leukemia Research, 2010
- Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989Blood, 2008
- Systematic screening at diagnosis of −5/del(5)(q31), −7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogeneticsCancer Genetics and Cytogenetics, 2004
- Deletion of 5q31 and 7q31 in patients with stable melphalan treated multiple myelomaCancer Genetics and Cytogenetics, 2004
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute LeukemiaNew England Journal of Medicine, 1979